Core Viewpoint - Changjiang Life Science Technology (00775) issued a profit warning, expecting a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a profit of HKD 1 million in the same period of 2024, primarily due to increased R&D investments [1]. Group 1 - The company's stock dropped over 5% following the profit warning, trading at HKD 0.95 with a transaction volume of HKD 5.7489 million at the time of reporting [1]. - The expected loss marks a significant shift from the previous year's profit, indicating a strategic decision to enhance research and development efforts [1]. - Overall, the company's operations have remained stable during the reporting period and up to the date of the announcement [1].
港股异动｜长江生命科技(00775)盈警后跌超5% 预计中期取得股东应占亏损约1.5亿港元